Schizophrenia is one of the leading causes of disability in the United States, characterized by delusions, hallucinations, and disorganized thoughts and behavior that profoundly affect a patient’s ability to function. Despite the availability of antipsychotic medications, treatment selection for schizophrenia has historically relied on trial and error, with no laboratory tests or biological markers to guide clinicians toward the therapy most likely to work for a given patient. A new study from the Feinstein Institute for Medical Research now offers a meaningful step toward changing that.
At FOMAT, CNS and psychiatric research represent areas where personalized medicine can have a transformative impact on patient outcomes. Schizophrenia disproportionately affects underserved communities who face the greatest barriers to consistent psychiatric care, making research like this especially relevant to our mission. The use of polygenic risk scores to guide treatment selection is exactly the kind of precision medicine approach that future clinical trials will need to incorporate to serve diverse populations effectively.
Using Genetics to Predict Schizophrenia Treatment Response
The study, published in the American Journal of Psychiatry, was led by Todd Lencz, professor at the Feinstein Institute, and Jian Ping Zhang, MD, assistant professor and lead author. Rather than testing for a single gene, the research team used polygenic risk scores, a relatively new approach that calculates the combined effects of thousands of genetic variants distributed across the entire genome.
As Dr. Zhang explained, polygenic risk scores better capture the complex genetic architecture of schizophrenia than single gene tests, making them a more practical and comprehensive tool for predicting how a patient will respond to treatment. The study focused specifically on patients experiencing their first episode of schizophrenia, testing whether genetic information collected at the outset could predict ultimate response to antipsychotic medications before any trial and error period began.
What the Schizophrenia Polygenic Risk Score Findings Revealed
The results showed that patients with higher polygenic risk scores, meaning a greater overall genetic burden of illness, were significantly less likely to respond to conventional antipsychotic treatment. This finding held up when tested in two independent patient cohorts drawn from an international collaboration between Feinstein Institute researchers and scientists across Europe, substantially strengthening the validity of the results.
The ability to replicate findings across independent cohorts is a critical standard in psychiatric genetics research, where population variability and the complexity of mental illness make single cohort results difficult to generalize. The fact that this association was confirmed across geographically and demographically distinct groups suggests the polygenic risk score approach has genuine predictive utility for schizophrenia treatment planning.
Why This Matters for Precision Medicine in Schizophrenia Care
The current standard of care for schizophrenia places a substantial burden on patients, families, and healthcare systems. When first line antipsychotic medications fail, patients may spend weeks or months on an ineffective treatment before an alternative is tried, during which time symptoms persist and quality of life deteriorates. Clinicians have no objective tool to guide initial drug selection, which means the burden of that uncertainty falls directly on already vulnerable patients.
Polygenic risk scores could change that dynamic by providing a biological basis for treatment decisions before therapy begins. According to Feinstein Institute president Kevin J. Tracey, MD, the work by Lencz and Zhang represents a major advance in precision medicine for schizophrenia, with therapy tailored to a patient’s genetic profile offering a meaningful improvement over existing trial and error approaches.
Next Steps in Schizophrenia Genetics Research
The research team plans to expand the study with the goal of developing formal clinical guidelines for the use of polygenic risk scores and other predictors, including neuroimaging, in schizophrenia treatment. As these tools are refined and validated in larger and more diverse populations, they have the potential to transform psychiatric care by bringing it closer to the precision medicine standards already established in oncology and other fields.
For the full source, see the original publication in the American Journal of Psychiatry.